[Palliative embolization of kidney tumors using iodol-marked Ethibloc].
In 59 patients having non-operable malignant renal tumours, palliative trans-catheter embolization was performed. In 42 of them follow-up observations were realized over 18 months. The average survival rate was then 43% of cases. Local tumour growth was documented in 9 patients (23%) due to recanalization of the embolized arteries (13%) and to non-occluded collateral vessels (10%). The choice of suitable embolizing materials mainly influences the therapeutic result: Oily contrast labeled amino-acid Ethibloc is considered to be the material of choice for safe application and reliable vascular distribution causing persisting occlusion of the renal arteries.
D000368:Aged; D003973:Diatrizoate; D004338:Drug Combinations; D004621:Embolization, Therapeutic; D005227:Fatty Acids; D005260:Female; D006801:Humans; D007459:Iodized Oil; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011409:Propylene Glycols; D011506:Proteins / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D015028:Zein
D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D011506:Proteins; D003973:Diatrizoate; D007459:Iodized Oil; D015028:Zein; C020481:alcoholic prolamine solution
Palliative Nierentumorembolisation mittels Jodöl-markiertem Ethibloc.